BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22126138)

  • 1. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
    Izadi H; Grundy JE; Bose R
    Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
    Reiss R; Gaylor D
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
    Foronda NM; Fowles J; Smith N; Taylor M; Temple W
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
    Gaylor DW; Aylward LL
    Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
    Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an occupational exposure limit for n-propylbromide using benchmark dose methods.
    Stelljes ME; Wood RR
    Regul Toxicol Pharmacol; 2004 Oct; 40(2):136-50. PubMed ID: 15450717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of benchmark dose for occupational epidemiology in lead exposure.
    Lin T; Xiao-Ting L; Ai G; Qiu-Ying L; Tai-Yi J
    Toxicol Mech Methods; 2008; 18(4):363-7. PubMed ID: 20020903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benchmark dose and the three Rs. Part I. Getting more information from the same number of animals.
    Slob W
    Crit Rev Toxicol; 2014 Aug; 44(7):557-67. PubMed ID: 25000332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration.
    Willhite CC; Ball GL; McLellan CJ
    J Toxicol Environ Health B Crit Rev; 2008 Feb; 11(2):69-146. PubMed ID: 18188738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current modeling practice may lead to falsely high benchmark dose estimates.
    Ringblom J; Johanson G; Öberg M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):171-7. PubMed ID: 24662478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
    Sand S; von Rosen D; Victorin K; Filipsson AF
    Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benchmark dose approaches in chemical health risk assessment in relation to number and distress of laboratory animals.
    Oberg M
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):451-4. PubMed ID: 20800084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing experimental designs for benchmark dose calculations for continuous endpoints.
    Kuljus K; von Rosen D; Sand S; Victorin K
    Risk Anal; 2006 Aug; 26(4):1031-43. PubMed ID: 16948695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.